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In vitro studies have shown that enteroviruses employ strategies that may impair the ability of DCs to trigger
T cell immunity, but it is unclear how these viruses affect DCs in vivo. Here, we evaluate the effects of wild-
type (wt) coxsackievirus B3 on DCs in vitro and in a murine model in vivo. Although CVB3 does not
productively infect the vast majority of DCs, virus infection profoundly reduces splenic conventional DC
numbers and diminishes their capacity to prime naı¨ve CD8þ T cells in vitro. In contrast to recombinant CVB3,
highly pathogenic wt virus infection signiﬁcantly diminishes the host’s capacity to mount T cell responses,
which is temporally associated with the loss of CD8aþ DCs. Our ﬁndings demonstrate that enterovirus
infection substantially alters the number, heterogeneity, and stimulatory capacity of DCs in vivo, and these
dramatic immunomodulatory effects may weaken the host’s capacity to mount antiviral T cell responses.
& 2012 Elsevier Inc. All rights reserved.Introduction
Dendritic cells (DCs) are specialized antigen presenting cells that
link the immediate innate immune response to viral infection with
the subsequent generation of an adaptive immune response (Lee
and Iwasaki, 2007). DCs comprise 2 major groups, plasmacytoid DCs
(pDC) and conventional DCs (cDC). pDCs play an important role in
shaping the innate and adaptive antiviral immune responses by
their ability to secrete large amounts of type I interferon (IFN) in
response to viral nucleic acid recognition (Gilliet et al., 2008; Swiecki
and Colonna, 2010b). Although pDCs are capable of antigen pre-
sentation (Villadangos and Young, 2008), it is the cDCs that play a
major role in priming virus-speciﬁc T cell responses (Heath and
Carbone, 2009; Lopez-Bravo and Ardavin, 2008). cDCs in the spleen
can be divided into 3 major subsets: CD8aþ DCs, CD4þ DCs, and
CD8CD4 ‘‘double negative’’ DCs. These subsets also are found in
peripheral lymph nodes, along with other subsets of migratory
conventional DCs (Heath and Carbone, 2009; Lopez-Bravo and
Ardavin, 2008). In addition, the inﬂammatory environment gener-
ated by virus infection can trigger the differentiation of monocyte-
derived DCs that contribute to antiviral immunity and stimulatell rights reserved.
all).virus-speciﬁc T cell responses (Dominguez and Ardavin, 2010; Leon
and Ardavin, 2008). Studies have shown that cDC subsets exert
distinct functions in activating antiviral T cell responses. CD8aþ DCs
are particularly efﬁcient at capturing apoptotic cells and priming
virus-speciﬁc CD8þ T cell responses. In contrast, CD8a DCs are
specialized for processing and presentation of antigens onMHC class
II and preferentially trigger CD4þ T cell responses (Lopez-Bravo and
Ardavin, 2008; Segura and Villadangos, 2009; Shortman and Heath,
2010; Villadangos and Schnorrer, 2007). The functional specializa-
tion of CD8aþ and CD8a subsets may be related to differences in
their expression of viral RNA sensors and/or machinery involved in
antigen processing and presentation (Dudziak et al., 2007; Luber
et al., 2010).
Type B Coxsackieviruses (CVB) are important human pathogens
that belong to the Picornavirus family and human enterovirus B
genus. A considerable proportion of CVB infections trigger severe
acute and chronic diseases and cause morbidity and mortality,
particularly in infants, young children, and immunocompromised
individuals (Modlin and Rotbart, 1997; Romero, 2008; Whitton,
2002). CVB are the most common cause of infectious myocarditis, a
serious disease that can lead to dilated cardiomyopathy and cardiac
failure (O’Connell, 1987; Sole and Liu, 1993; Tam, 2006). These
viruses also can induce other diseases, including pancreatitis, aseptic
meningitis, and encephalitis (Daley et al., 1998; Feuer et al., 2005;
Huber and Ramsingh, 2004; Mena et al., 2000; Rhoades et al., 2011;
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both humoral and cell mediated-immunity (Kemball et al., 2010a;
Kemball et al., 2010b). CD8þ T cell responses directed at native
epitopes in the CVB polyprotein are remarkably weak (Jakel et al.,
2009; Varela-Calvino et al., 2004; Voigt et al., 2010; Weinzierl et al.,
2008a) and, in order to enhance our ability to detect virus-speciﬁc
T cells, our laboratory generated recombinant CVB3 (rCVB3) that
encode well characterized CD8þ and/or CD4þ T cell epitopes from
lymphocytic choriomeningitis virus (LCMV). Despite their ability to
replicate to high titers in vivo, wild-type (wt) CVB3 and rCVB3
induce minimal T cell activation and weak endogenous virus-
speciﬁc T cell responses (Crocker et al., 2007; Kemball et al., 2008;
Slifka et al., 2001). Using epitope-speciﬁc CD8þ transgenic T cells as
sensors to evaluate in vivo antigen presentation by rCVB3, we
demonstrated that this virus almost completely evades presentation
through the MHC class I pathway (Kemball et al., 2009). This
strategy is extremely effective, as naı¨ve virus-speciﬁc CD8þ trans-
genic T cells fail to expand in rCVB3-infected mice. Memory CD8þ
T cells, however, can respond to a lower level of antigen presenta-
tion than their naı¨ve counterparts (Slifka and Whitton, 2001), and
we found that epitope-speciﬁc memory CD8þ T cells were activated
by rCVB3 infection in vivo (Kemball et al., 2008). Therefore, we have
suggested that the quantity of MHC class I/viral peptide complex
that is expressed on a CVB3-infected cell is too low to trigger strong
responses by naı¨ve CD8þ T cells, but is sufﬁcient to activate memory
CD8þ T cells.
Activation of naı¨ve CD8þ T cells is profoundly dependent upon
antigen presentation by cDCs. However, the effects of coxsackie-
virus infection on dendritic cell populations in vivo are not well
understood. In vitro studies have shown that other enteroviruses
can infect DCs and employ tactics that may impair the ability of
DCs to prime robust T cell responses. Poliovirus, a close relative of
CVB, can inhibit protein synthesis in DCs and dampens MHC class
I antigen presentation (Choe et al., 2005; Deitz et al., 2000; Wahid
et al., 2005); the virus also inhibits proinﬂammatory cytokine
secretion and the expression of antiviral cytokine receptors (Dodd
et al., 2001; Neznanov et al., 2001). Furthermore, echovirus
infection limits the ability of DCs to up-regulate costimulatory
molecules and to produce cytokines following TLR stimulation
(Kramer et al., 2007). However, it is not known whether picorna-
viruses exert similar effects on DCs in vivo. A recent study
reported that positive and negative strand CVB3 RNA was present
in DCs following infection in vitro and in vivo but, in both cases,
viral replication was incomplete and the infection was non-
productive (Weinzierl et al., 2008b). It is unclear what frequency
of DCs is infected by CVB3 in vivo, and whether the virus can
modulate presentation of viral epitopes at the surface of these
professional antigen presenting cells. Furthermore, infection of
the host may indirectly affect DCs, quantitatively and/or qualita-
tively, potentially limiting their ability to trigger T cell responses.
We have previously shown that rCVB3 did not globally suppress
the host’s capacity to mount CD8þ T cell responses (Kemball
et al., 2009); however, rCVB3 are attenuated in vivo, and we
considered it vital to determine if highly-pathogenic wild-type
(wt) virus profoundly affects one or more DC subsets in vivo, and
whether such changes are associated with a reduced ability of the
host to trigger strong antiviral T cell responses.
In this study, we have used the murine model of CVB3 infection to
evaluate the effects of the wt virus on dendritic cells in vivo. We
report that, for the vast majority of DCs in vitro and in vivo, we
observe neither productive infection nor viral protein synthesis.
Nevertheless, wtCVB3 infection rapidly induces phenotypic changes
in conventional DCs in vivo, and also dramatically reduces their
abundance. In vitro analyses show that splenocytes taken from
wtCVB3-infected mice have a diminished capacity to stimulate naı¨ve
T cells; however, on a per-cell basis, DCs from wtCVB3-infected miceremain capable of triggering CD8þ T cell division. In contrast to
rCVB3, wt virus infection signiﬁcantly diminished the host’s capacity
to mount T cell responses, which was temporally associated with the
loss of CD8aþ DCs. To our knowledge, our study is the ﬁrst to
precisely enumerate cDCs during picornavirus infection, and to show
that their abundance is substantially altered in vivo.Results
CVB3 infection substantially alters conventional and plasmacytoid
dendritic cell populations in vivo
We ﬁrst examined whether CVB infection had any quantitative
or qualitative effect on conventional and plasmacytoid DCs
in vivo. Mice were inoculated with 103 pfu of wild-type CVB3
(wtCVB3). Virus replicated rapidly and reached very high titers in
the pancreas on day 2–4 post infection (p.i.) (41010 pfu/g), then
declined by day 6 (Fig. 1(A)). In contrast to many acute virus
infections, which induce mild or moderate splenomegaly together
with strong virus-speciﬁc CD8þ T cell responses, acute infection
with wtCVB3 was associated with a gradual and substantial
reduction in the total number of splenocytes, which declined
4-fold by day 8 compared to uninfected mice (Fig. 1(B)).
Because primary virus-speciﬁc T cell responses are usually
initiated within a few days of infection, we analyzed conventional
and plasmacytoid DC numbers on days 2, 4, 6, and 8 p.i. cDCs
were classiﬁed as CD11chi and negative for expression of lineage
markers for T cells, B cells, and NK cells (CD3CD19CD49b).
pDCs were deﬁned by being CD11c intermediate (CD11cint),
lineage negative, and expressing high levels of bone marrow
stromal cell antigen 2 (BST-2, also known as mPDCA-1). cDCs
were readily detected in uninfected mice, but declined in CVB3-
infected mice after day 2, and very few of these cells remained by
day 8 (Fig. 1(C) and (E)). pDCs also were detected in uninfected
mice, and their total number increased 8-fold in virus-infected
mice by day 6 and then declined by day 8 (Fig. 1(D)); their
frequency, too, increased markedly between 4 and 6 days p.i.
(Fig. 1(F)). Thus, CVB3 infection substantially alters the frequency
and number of both conventional and plasmacytoid DCs.
CVB3 infection dramatically reduces the subset of conventional
dendritic cells that is thought to be the most potent inducer of
antiviral CD8þ T cell responses
Conventional DCs, and in particular their CD8aþ subset, are
known to be very efﬁcient at priming virus-speciﬁc CD8þ T cell
responses (Shortman and Heath, 2010). To evaluate the effects of
wtCVB3 infection on these cells, splenocytes were harvested from
infected mice on days 2, 4, 6, and 8, stained with antibodies to
discriminate among the 3 major subsets of conventional DCs,
and analyzed by ﬂow cytometry. As expected, and in order of
decreasing frequency, CD4þ , double negative, and CD8aþ subsets
were detected among CD11chi DCs in uninfected spleens
(Fig. 2(A), top left panel). The frequency of CD8aþ DCs increased
slightly on day 2, and then declined sharply thereafter; very few
CD8aþ DCs remained in the spleen from day 4 onward (Fig. 2(A),
(C) and (D)). The frequency of CD4þ DCs also declined dramati-
cally following CVB3 infection (Fig. 2(A) and (C)) and, by 8 days
p.i., the number of these cells had decreased almost 40-fold
compared to uninfected animals (Fig. 2(D)). Double negative
DCs were proportionately less affected by infection, and became
the dominant subset by day 4 (as a percentage of all DCs,
Fig. 2(A) and (C)). However, the absolute number of all three
cDC subsets declined over the course of infection (Fig. 2(D)). We
next focused on the CD205þ subset of CD8aþ cDCs. These cells
Fig. 1. CVB3 infection substantially alters the numbers of conventional and plasmacytoid dendritic cells in vivo. Mice were infected with wtCVB3, and the virus titers in
the pancreas (A) (titers shown for individual mice, with mean), and total number of mononuclear cells in the spleen (B) were determined at the indicated time points p.i.
Data show the mean7SEM of 2–12 mice per time point, combined from 4 independent experiments. Conventional and plasmacytoid DCs in the spleen were analyzed by
ﬂow cytometry on days 2, 4, 6, and 8 p.i. (C) Total number of cDCs in the spleen. (D) Total number of pDCs in the spleen. Data show the mean7SEM of 2–9 mice per time
point, combined from 3 independent experiments. Representative contour plots are shown, and the rectangular gates identify cDCs [CD11chi and lineage negative
(CD3CD19CD49b), panel E] and pDCs [CD11cint and mPDCA-1hi (plots are gated on lineage negative cells), panel F]; the numbers shown on the contour plots are the
percentages of conventional or plasmacytoid DCs among all cells in the plot.
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are thought to be specialized for the processing and presentation of
exogenous antigens on MHC class I (cross-presentation) (Dudziak
et al., 2007; Lopez-Bravo and Ardavin, 2008; Villadangos and
Schnorrer, 2007). Previous ﬁndings from our laboratory have
suggested that cross-priming is inefﬁcient during CVB3 infection
(Kemball et al., 2009; Kemball et al., 2008), and led us to question
whether the virus modiﬁes the CD8aþCD205þ cDC subset in vivo.
The frequency and number of CD8aþCD205þ cDCs shared similar
kinetics with the total CD8aþ cDC population, and virus infection
led to a dramatic reduction in number of CD8aþCD205þ cDCs by
day 4 (Fig. 2(B) and (E)). Taken together, these data show that CVB3
infection substantially modiﬁes the relative proportions of cDC
subsets, and is associated with a profound reduction in the number
of all cDC subsets, including the cells that are optimally suited to
prime virus-speciﬁc CD8þ T cell responses.
To assess whether this loss of DCs occurs in other secondary
lymphoid organs, we evaluated the effects of wtCVB3 infection
on DC populations in the pancreatic lymph nodes (pLNs). The
frequency of CD8aþ DCs in the pLNs declined sharply after
day 2 p.i. in a similar manner to CD8aþ DCs in the spleen
(Fig. 2(C) and Fig. 3(A)). The total number of CD11chi DCs, and
the number of all three DC subsets also declined after infection;
few CD8aþ DCs remained in the pLNs from day 4 onward
(Fig. 3(B)–(D)). In addition, very few CD11chi cDCs were present
in virus-infected pancreas; although other lymphocytes (T cells,
macrophages, neutrophils) were readily detected in this organ
following infection, DCs were present at a very low level and
their numbers did not increase with infection (data not shown).Overall, CVB3 infection leads to a similar reduction in cDCs in the
spleen and pLNs.
CVB3 infection does not globally inhibit the up-regulation of MHC
and costimulatory molecules on conventional dendritic cells in vivo
Besides reducing the number of DCs available for presenting
viral antigen and/or priming virus-speciﬁc T cells in vivo, CVB3 also
could avoid activating naı¨ve T cells by limiting the expression of
MHC and costimulatory molecules on the remaining DCs. To assess
this, mice were infected with wtCVB3, and the cell surface
phenotypes of the three major subsets of cDCs were analyzed.
The levels of MHC class I, class II, and CD80 increased 2-fold on
CD8aþ DCs by day 2, while CD40 and CD86 were more strongly
up-regulated (3-fold and 5-fold, respectively) (Fig. 4, top row).
Because of the profound reduction in the frequency and number
of CD8aþ DCs by day 4 (Fig. 2), we were unable to track the
phenotype of this subset at later time points. The CD4þ and double
negative subsets of DCs also expressed elevated levels of MHC class
I, class II, CD40, and CD80 by day 2, although the increase was quite
modest (r2-fold); the level of these molecules was maintained,
or decreased slightly, between 2 and 6 days post infection (Fig. 4,
middle and bottom rows). In contrast, CD86 expression was
substantially up-regulated on CD4þ and double negative subsets
on day 2 (4-fold), and then declined by day 4 (middle and
bottom rows). Overall, the 3 major subsets of cDCs in the spleen
displayed an activated phenotype within 48 h of CVB3 infection,
and strongly up-regulated the costimulatory molecule CD86. A
recent study examined changes in CD11cþ DC phenotype in vivo at
Fig. 2. CVB3 infection profoundly reduces the numbers of CD8aþ , CD4þ , and double negative conventional dendritic cells. Mice were infected with wtCVB3, and
splenocytes were harvested and analyzed by ﬂow cytometry on days 2, 4, 6, and 8 p.i. Representative contour plots are shown ((A) and (B)), and were gated to include
CD11chi lineageneg cells. The numbers indicate the proportion of the various subsets of cDCs (CD8aþ , CD4þ , double negative, and CD8aþCD205þ) in each quadrant, as a
percentage of all CD11chi lineageneg cells. (C) Frequency of CD8aþ , CD4þ , and double negative cDCs (as a percentage of CD11chi lineageneg cells) in the spleen. (D) Total
number of CD8aþ , CD4þ , double negative cDCs in the spleen. (E) Total number of CD8aþCD205þ cDCs in the spleen. Data show the mean7SEM of 2–9 mice per time
point, combined from 3 independent experiments.
Fig. 3. CVB3 infection diminishes the number of conventional dendritic cells in lymph nodes. Mice were infected with wtCVB3, and lymphocytes were harvested from
pancreatic lymph nodes (pLNs) and analyzed by ﬂow cytometry on days 2, 4, and 6 p.i. (A) Frequency of CD8aþ , CD4þ , and double negative cDCs (as a percentage of
CD11chi lineageneg cells) in the pLNs. (B) Total number of CD11chi cDCs in the pLNs. (C) Total number of CD8aþ , CD4þ , and double negative cDCs in the pLNs. (D) Total
number of CD8aþCD205þcDCs in the pLNs. Data show the mean7SEM of 3–4 mice per time point, combined from 2 independent experiments.
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in MHC class I and II expression at this time point (Rahnefeld et al.,
2011). In contrast, our detailed analysis of cDC subsets revealed
that CD8aþ DCs up-regulate these MHC molecules by 48 h p.i.
(Fig. 3, top row). These data suggest that the virus does not prevent
the activation of splenic cDCs; on the contrary, CD8aþ DCs display
a mature phenotype and appear poised to prime CVB3-speciﬁc
CD8þ T cells within the ﬁrst 2 days of infection.Infection with a recombinant virus expressing DsRed suggests that
very few DCs are infected in vivo
One obvious explanation for the dramatic reduction in DC
numbers was that the virus directly infects DCs. In support of this
idea, a recent study found that CVB3 could infect DCs, and
both positive and negative strand viral RNA was detected in
DCs in vitro and in vivo (Weinzierl et al., 2008b). However, the
Fig. 4. Conventional dendritic cells up-regulate the expression of MHC and costimulatory molecules following virus infection. Mice were infected with wtCVB3, and the
level of cell surface expression of MHC class I, MHC class II, CD40, CD80, and CD86 on cDCs in the spleen was measured by ﬂow cytometry on day 2, 4, and 6. The
expression kinetics for MHC and costimulatory molecules are shown for each of the 3 major cDC subsets (CD8aþ , top row; CD4þ , middle row; and double negative,
bottom row). The fold change in the geometric mean ﬂuorescence intensity of each protein over the course of infection was normalized and compared to the level of
expression on cells from uninfected mice (day 0). Data show the meanþSEM of 4–9 mice per time point, combined from 3 independent experiments. The expression level
of these proteins on the CD8aþ subset could not be determined after day 2 because these cells were too few in number.
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replication was incomplete and non-productive, and viral protein
synthesis within the cells was not assessed. Thus, we have
assessed these issues, in vivo and in vitro. To investigate whether
CVB3 proteins were expressed in cDCs in vivo, we used a rCVB3
that expresses DsRed (DsRed-CVB3, Ref. Tabor-Godwin et al.,
2010). Mice were infected with this virus and, to conﬁrm infec-
tion and DsRed expression, we evaluated virus titers at days 1 and
2 p.i., and used confocal microscopy to analyze tissue sections;
the studies focused on the pancreas, a primary target organ of
CVB3 in vivo. Viral titers were high (109 pfu/g) at both time
points, and DsRed expression was readily detected in many
pancreatic acinar cells at 2 days p.i. (Fig. 5(A)), indicative of
successful infection and marker protein expression in vivo. Next
we evaluated DsRed expression in DCs from the spleen and
pancreatic lymph nodes (pLNs) at days 1 and 2 p.i., using ﬂow
cytometry. Several thousand DCs were analyzed in both tissues
(37103 cells per sample), but the frequency of DsRedþ DCs
was very low and similar to the background level seen in
uninfected mice (Fig. 5(B)). The differences in the percentage
of DsRedþ DCs between uninfected and infected mice were not
statistically signiﬁcant by a t-test comparing uninfected versus day
1 (spleen p¼0.6266, pLNs p¼0.0939) and uninfected versus day 2
(spleen p¼0.7664, pLNs p¼0.2746). Flow cytometric analysis of
DsRed expression in CD8aþ , CD4þ , and double negative subsets of
conventional DCs in the spleen yielded similar results (data not
shown). Although very slightly more DsRedþ DCs were identiﬁed
in infected mice, the intensity of the ﬂuorescent signal was low,
and comparable to the negative control ﬂuorescence intensity
observed in DCs from uninfected mice (Fig. 5(B)). We conclude
that very few, if any, DCs express this CVB3 protein following
infection in vivo.
CVB3 and dendritic cells in vitro: No productive infection, protein
synthesis, or down-regulation of MHC expression
The above data suggest that DCs are not a primary target
for CVB3 infection in vivo, but we considered it important to
determine if DCs might be susceptible to in vitro infection. An
in vitro approach allowed us to generate large numbers of DCs,expose them to CVB3 synchronously at high moi, and characterize
the progress of infection at deﬁned time points thereafter. Two
different populations of DCs were analyzed: immature C57BL/6
bone marrow monocyte-derived DCs (cultured with GM-CSF);
and DC2.4 cells, an immortalized cell line generated from C57BL/6
monocyte-derived DCs (Shen et al., 1997). DCs were exposed to
wtCVB3, or to a recombinant CVB3 expressing eGFP (eGFP-CVB3),
at a high multiplicity of infection (MOI¼10), or were mock
infected; 22–23 h later the cells were stained for intracellular
expression of the viral capsid protein VP1 and analyzed by ﬂow
cytometry to detect VP17eGFP. HeLa cells were infected as a
positive control. As expected, viral proteins were readily detected
in HeLa cells (6 h post infection); for both viruses, 90% of HeLa
cells were GFPþ and/or VP1þ (Fig. 6(A), top row). In contrast, we
did not detect a signiﬁcant number of DCs that were VP1þ or
GFPþ; 96.5–99.5% of DCs were negative for CVB protein expres-
sion (Fig. 6(A), middle and bottom rows). Furthermore, no
increase in virus titer was detected in infected DC2.4 or BMDC
cultures, nor did we observe virus-induced cytopathic effect (not
shown). Thus, there is little evidence that the majority of DCs can
be productively infected by CVB3; indeed, the absence of viral
protein synthesis in DCs suggests that even non-productive
infection is very unusual. Moreover, no substantial changes to
MHC class I, or II was observed on BMDCs 18–24 h after exposure
to CVB3 in vitro (Fig. 6(B)); this was true, too, of CD86 (not
shown). Taken together, the data in Fig. 5 and Fig. 6 suggest that
the great majority of DCs are resistant to CVB3 infection. There-
fore, the dramatic reduction in DC numbers that follows CVB3
infection in vivo does not appear to result from direct infection-
mediated cell death of DCs (Figs. 1 and 2).
The loss of conventional dendritic cells in CVB3-infected mice is
associated with weaker T cell responses to a secondary virus infection
We have previously shown that infection of mice with rCVB3
does not weaken their ability to mount T cell responses against a
subsequent infection with LCMV. Rather, mice that receive rCVB3
three days before LCMV mount larger LCMV-speciﬁc T cell
responses than mice infected with LCMV alone (Kemball et al.,
2009). However, rCVB3 are attenuated in vivo, and in light of the
Fig. 5. Few, if any, dendritic cells are infected by CVB3 in vivo. Mice were infected with DsRed-CVB3, and were sacriﬁced 1 or 2 days later. (A) Viral titers in the pancreas
were measured (graph) and DsRed protein was imaged by confocal microscopy of vibratome sections of pancreas; scale bar¼30 mm. (B) The frequency of DsRedþ DCs in
the spleen and pancreatic lymph nodes was analyzed by ﬂow cytometry on days 1 and 2. Contour plots are gated on DCs [CD11chi and ‘‘lineage’’ negative
(CD3CD19CD49b) cells for the spleen (top row), and CD11cint-hi lineage cells for the pancreatic lymph nodes (bottom row)]. The large rectangular gates shown
on representative contour plots identify DsRedþ cells, and the numbers shown are the percentage of DsRedþ cells among all cells in the plot. 37.5103 DCs were
analyzed in these plots. Bar graphs display the mean7SEM of 3 mice per group. No statistically signiﬁcant differences were detected among these groups by a t-test.
Fig. 6. wtCVB3 has little effect on dendritic cells in vitro. (A) Bone marrow monocyte-derived dendritic cells (BMDCs) and the DC2.4 dendritic cell line were evaluated for
their susceptibility to CVB3 infection; HeLa cells were infected as a positive control. HeLa, DC2.4, and BMDCs were incubated with wtCVB3 or eGFP-CVB3 (MOI¼10) for 1 h,
or mock infected. Inoculum was removed, and cells were harvested (HeLa cells, 6 h p.i.; BMDC and DC2.4, 24 h p.i.), stained for intracellular VP1, and the percentage of cells
expressing VP17eGFP was determined by ﬂow cytometry. Representative contour plots are shown for each cell type, and the numbers indicate the proportion of cells in
each quadrant, as a percentage of all cells in the plot (VP1þ , upper left quadrant; eGFPþ , lower right quadrant; VP1þeGFPþ , upper right quadrant). (B) BMDCs (cultured
with GM-CSF) were infected with wtCVB3 (MOI¼100), or left uninfected, and the surface expression of MHC class I and II were analyzed by ﬂow cytometry 18 h p.i.
Histograms are gated on CD11cþCD11bþ cells, and show the expression of MHC class I or II (black lines); isotype control staining is shaded gray. The number on each
histogram indicates the geometric mean ﬂuorescence intensity of MHC class I or II. Data are representative of 2 independent experiments.
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wtCVB3 infection, we considered it important to determine if
the highly pathogenic wt virus would reduce the ability of the
host to mount a subsequent antiviral T cell response to LCMV.Studies have shown that priming of LCMV-speciﬁc CD8þ T cells
requires DCs, and that CD8aþ cDCs are the predominant subset
that initiates this response (Belz et al., 2005; Probst and van den,
2005). We reasoned that the loss of CD8aþCD205þ DCs in the
C.C. Kemball et al. / Virology 429 (2012) 74–9080spleen of wtCVB3-infected mice between 2 and 4 days p.i.
(Fig. 2(B) and (E)) might be associated with diminished T cell
responses to LCMV that was inoculated 3 or 4 days post-wtCVB3.
Therefore, groups of mice were infected with wtCVB3, and then
co-infected with LCMV 3 or 4 days later. The frequencies of total
CD8þ and CD4þ T cells, and LCMV-speciﬁc CD8þ and CD4þ T cell
responses, were analyzed in the spleen 7 days after LCMV
infection. Our analyses of co-infected mice (presented in Figs.
7–12) were carried out in animals that exhibited clear indications
of a robust CVB3 infection, by meeting three criteria: the presence
of infectious virus in the feces (determined by plaque assay,
2 days after CVB3 infection); the presence of infectious virus in
the pancreas (assayed at the time point of animal sacriﬁce and T
cell analysis); and the presence of calcium deposits in the
peritoneal cavity, a classic phenotypic signature of CVB3 infection
and pancreatic disease (Mena et al., 2000). The total number of
mononuclear cells in the spleen (Fig. 7(A)) and the frequency of
splenic CD8þ T cells (Fig. 7(B)) were signiﬁcantly reduced (2–3
fold) in mice that had received wtCVB3 3 or 4 days before LCMV,
as compared to mice that received LCMV infection alone. In
contrast, the frequency of CD4þ T cells was not signiﬁcantly
altered by CVB3 co-infection (Fig. 7(C)). In mice that had received
wtCVB3 3 or 4 days before LCMV, the total numbers of GP33- and
NP396-speciﬁc CD8
þ T cells were signiﬁcantly lower than in mice
infected only with LCMV; when 4 days elapsed between wtCVB
and LCMV infections, the LCMV-speciﬁc T cell responses were 10-
to 14-fold lower (Fig. 7(D)). Mice that had received wtCVB3 4 days
before LCMV did not have a lower frequency of total CD4þ T cells
(Fig. 7(C)), but the overall reduction in splenocyte numbers
(Fig. 7(A)), combined with a reduced frequency of GP61-speciﬁc
cells among total CD4þ T cells (not shown), led to a strong and
signiﬁcant reduction in the total number of GP61-speciﬁc CD4
þ T
cells, to an extent very similar to that observed for CD8þ T cells
(14-fold; Fig. 7(E)).Fig. 7. CVB3-infected mice mount weaker CD4þ and CD8þ T cell responses to a seconda
with LCMV (3 or 4 days after the primary infection with CVB3). An additional group of m
were analyzed 7 days after LCMV infection by ﬂow cytometry. (A) Total number of mono
spleen, as a percentage of total mononuclear cells. ((D) and (E)) Splenocytes were stimu
GP33 and NP396 peptides (D), and GP61 peptide (E) were determined by ﬂow cytometry. D
experiments (nnpo0.01, nnnpo0.001).The effect of wtCVB3 on T cell responses to LCMV appears early, but
its impact is time-dependent
The data in Fig. 7 show that wtCVB3 infection limits the T cell
response to LCMV administered 4 days later, a time point at
which CD8aþCD205þ DCs in the spleen have reached their
numerical nadir (Fig. 2). In contrast to their status at day
4 following wtCVB3 infection, CD8aþCD205þ DCs are abundant
in the spleen at day 2 p.i., and display and activated phenotype
(Fig. 2(B) and (E), Fig. 4). Therefore, we considered the possibility
that these abundant and highly-activated CD8aþ DCs might
enhance, rather than limit, T cell responses to LCMV that was
administered at this time point. To test this hypothesis, mice were
infected with wtCVB3, and co-infected with LCMV 2 days later. The
frequencies of total CD8þ and CD4þ T cells, and LCMV-speciﬁc
CD8þ and CD4þ T cell responses, were analyzed in the spleen on
day 5 and 7 after LCMV infection. Compared to mice that received
LCMV infection alone, the total number of mononuclear cells in the
spleen (day 7, Fig. 8(A)) and the frequency of splenic CD8þ T cells
(day 5 and 7, Fig. 8(B)) were signiﬁcantly reduced (2-fold) in co-
infected mice. In contrast, the frequency of CD4þ T cells was not
signiﬁcantly altered by CVB3 co-infection (Fig. 8(C)). The total
numbers of GP33- and NP396-speciﬁc CD8
þ T cells were signiﬁcantly
lower than in mice infected only with LCMV (Fig. 8(D) and (E)). Co-
infection with wtCVB3 had similar effects on the LCMV-speciﬁc
CD4þ T cell response; the total number of GP61-speciﬁc CD4
þ T
cells was reduced at both days 5 and 7 after LCMV infection
(Fig. 8(F)). The above evaluation of the LCMV-speciﬁc T cell
responses relied on a functional readout (IFNg production). Thus,
it was formally possible that the number of LCMV-induced T cells in
CVB3-infected mice was normal, and that the majority of the cells
were dysfunctional (IFNg-deﬁcient), rendering them undetectable
by the above assay. Therefore, we enumerated the cells using
appropriate MHC class I tetramers. Compared to mice infected withry virus infection. Groups of mice were infected with wtCVB3, and then co-infected
ice was infected only with LCMV. LCMV-speciﬁc CD8þ and CD4þ T cell responses
nuclear cells in the spleen. ((B) and (C)) Frequency of CD8þ and CD4þ T cells in the
lated with peptide, and the total numbers of T cells producing IFNg in response to
ata show the mean7SEM of 6 or 8 mice per group, combined from 2 independent
Fig. 8. The effect of wtCVB3 infection is more profound at the early stage of LCMV-speciﬁc T cell expansion. Mice were infected with wtCVB3 and co-infected with LCMV
2 days later. An additional group of mice was infected only with LCMV. LCMV-speciﬁc CD8þ and CD4þ T cell responses were analyzed 5 or 7 days after LCMV infection by
ﬂow cytometry. (A) Total number of mononuclear cells in the spleen. ((B) and (C)) Frequency of CD8þ and CD4þ T cells in the spleen, as a percentage of total mononuclear
cells. ((D), (E) and (F)) Splenocytes were stimulated with peptide, and the total numbers of T cells producing IFNg in response to GP33 (D), NP396 (E), and GP61 peptides
(F) were determined by ﬂow cytometry. Data show the mean7SEM of 6 or 8 mice per group, combined from 3 independent experiments. ((G) and (H)) The total number of
DbGP33 and D
bNP396 tetramer
þ CD8þ T cells in the spleen was determined by ﬂow cytometry. Data show the mean7SEM of 3 or 4 mice per group, combined from
2 independent experiments. Statistical signiﬁcance was determined by an unpaired t-test.
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merþCD8þ T cells was substantially reduced (410-fold) in co-
infected mice 5 days after LCMV (Fig. 8(G) and (H)), which parallels
the reduction in the total number LCMV-speciﬁc IFN-gþ CD8þ T
cells (Fig. 8(D) and (E)). Taken together, these ICCS and tetramer
data show that wtCVB3 infection is associated not with enhanced,
but rather with signiﬁcantly weaker CD8þ and CD4þ T cell
responses to LCMV, even if LCMV is administered shortly after
CVB3 (2 days later) when activated DCs are abundant in the spleen.
The effect of wtCVB3 on the magnitude of the LCMV-speciﬁc
CD8þ and CD4þ T cell responses varied with, and was dependent
upon, two distinct time intervals. First, the time allowed to elapsebetween the CVB3 and LCMV infections. When CVB3 was admi-
nistered only 2 days prior to LCMV, the responses to LCMV 7 days
later were only modestly reduced (Fig. 8(D)–(H)), while the
suppressive effects of CVB3 were much more pronounced when
4 days had elapsed between wtCVB and LCMV infections
(Fig. 7(D) and (E)). Second, the time point post-LCMV at which
the responses are measured. For CD8þ T cells (Fig. 8(D), (E),
(G) and (H)) the reduction in LCMV-speciﬁc responses was
markedly greater at day 5 post-LCMV (10–20-fold) compared
to day 7 (2–4-fold). A similar observation applies to CD4þ T
cells: the total number of GP61-speciﬁc CD4
þ T cells was strongly
reduced 5 days after LCMV (13-fold), but this numerical deﬁcit
Fig. 9. Conventional dendritic cell numbers are diminished in co-infected mice. Groups of mice were infected with wtCVB3, and then co-infected with LCMV. ((A) and (B))
Mice received LCMV 3 or 4 day after the primary infection with CVB3, and cDCs were analyzed 7 day after LCMV infection by ﬂow cytometry. ((C) and (D)) Mice received
LCMV 2 day after CVB3, and cDCs were analyzed on day 5 and 7 after LCMV infection. ((A) and (C)) Total number of cDCs in the spleen. ((B) and (D)) Total number of
CD8aþ , CD8aþCD205þ , CD4þ , and double negative cDCs in the spleen. Data show the mean7SEM of 2 or 3 mice per group ((A) and (B)), or 6–8 mice per group combined
from 3 independent experiments ((C) and (D)). Statistically signiﬁcant differences between uninfected and co-infected groups were detected by ANOVA (npo0.05,
nnpo0.01, nnnpo0.001).
Fig. 10. CVB3 infection does not dampen LCMV replication in co-infected mice.
Mice were infected with wtCVB3 and then co-infected with LCMV 2 days later.
Another group of mice received only LCMV. Five days after LCMV infection, RNA
was isolated from the spleen and liver and the number of LCMV genomes was
determined by quantitative real time RT-PCR. Data show the mean7SEM of 3 or
6 mice per group, combined from 2 independent experiments (npo0.05, deter-
mined by an unpaired t-test).
C.C. Kemball et al. / Virology 429 (2012) 74–9082was partially restored by day 7, with only a 3-fold difference
between co-infected mice and mice infected with LCMV alone
(Fig. 8(F)). Although the effects of wtCVB3 on the magnitude of
LCMV-speciﬁc T cell responses varies with these time intervals, in
all cases the LCMV-speciﬁc effector cells appear to be functionally
competent to produce IFNg.
Conventional dendritic cell numbers are diminished in co-infected
mice
To determine if co-infection with wtCVB3 and LCMV led to a
similar reduction in cDC numbers as wtCVB3 infection alone, thenumber of splenic DCs in co-infected mice was assessed at the
time points when LCMV-speciﬁc T cell responses were measured
ex vivo (day 5 and 7 post LCMV, Fig. 7 and Fig. 8). In mice that were
infected with wtCVB3 and co-infected with LCMV 3 or 4 days later,
the total number of CD11chi cDCs was signiﬁcantly diminished
7 days post LCMV infection (10 or 11 day post CVB3) (Fig. 9(A)).
Analysis of cDC subsets showed that the total number of CD8aþ
and CD4þ cDCs were most profoundly reduced (Fig. 9(B)). Similar
results were obtained in mice that were infected with wtCVB3 and
co-infected with LCMV 2 days later; DC numbers were signiﬁ-
cantly reduced at 5 and 7 days post LCMV infection (7 or 9 days
post CVB3) (Fig. 9(C) and (D)). Overall, the number of DCs did not
vary substantially between co-infected mice and mice infected
with wtCVB3 alone. Rather, cDC numbers were signiﬁcantly
diminished and to a similar extent in both groups of mice
(Figs. 1, 2 and 9).
The reduced T cell responses to LCMV do not result from lack of
replication, and LCMV antigen presentation by splenic APCs from
co-infected mice can trigger naı¨ve T cell proliferation
An alternative explanation for the reduced LCMV-speciﬁc T cell
response in co-infected mice is that CVB3 infection establishes a
microenvironment that suppresses LCMV replication, thereby
reducing the amount of viral antigen available for priming naı¨ve
LCMV-speciﬁc T cells. This possibility was assessed in two ways.
First, mice were infected with wtCVB3 and then infected with
LCMV 2 days later. A control group of mice received only LCMV.
Five days after LCMV infection, RNA was isolated from the spleen
and liver and the copy number of LCMV genomic S segment RNA
was determined by quantitative real time RT-PCR. At this time
point, mice infected with LCMV alone had 2107 genome
copies per mg of spleen, and 5106 per mg of liver; mice that
had been infected 2 days previously with wtCVB3 had a similar
genome load in the spleen, but signiﬁcantly elevated (6-fold)
load in the liver (Fig. 10). These data suggest that CVB3 does not
Fig. 11. In vitro stimulation assay: wtCVB3 delays, but does not prevent, expansion of LCMV-speciﬁc CD8þ T cells. Mice were infected with wtCVB3 and, 4 days later, were
co-infected with LCMV. Control mice received CVB3 alone, LCMV alone, or no virus. Splenocytes were harvested from infected mice 2 days after LCMV infection and/or
6 days post CVB3, and were incubated in vitro with magnetically puriﬁed, CFSE-labeled, P14 CD8þ transgenic T cells. An additional set of cultures included P14 cells
incubated with splenocytes from co-infected miceþ1 mM GP33–41 peptide. Duplicate wells were harvested on days 2, 3, or 4, and analyzed by ﬂow cytometry.
(A) Proliferation (loss of CFSE ﬂuorescence) of P14 T cells. Histograms are gated on CD8þThy1.1þ cells, and, for each histogram, the percentage of P14 cells that have
divided is shown; the gate used to deﬁne P14 division is shown by dotted lines in the upper left panel. (B) Kinetics of P14 T cell division in vitro. Data show the percentage
of total P14 cells in each well that have divided at least once, and are expressed as the mean7SEM of 3–7 mice per group (n¼1 for P14 cells incubated with uninfected
control splenocytes). (C) The frequency of cDC subsets in the splenocyte stimulator populations (prior to in vitro culture) was determined by ﬂow cytometry.
Representative contour plots are shown, and are gated on CD11chi lineageneg cells. The numbers indicate the proportion of cells in each quadrant, as a percentage of all
CD11chi lineageneg cells.
Fig. 12. Puriﬁed dendritic cells from LCMV-infected or co-infected mice are similarly capable of stimulating T cell proliferation in vitro. Mice were infected with wtCVB3
and, 4 days later, were co-infected with LCMV. Control mice received CVB3 alone, LCMV alone, or no virus. Splenocytes were harvested from infected mice 2 days after
LCMV infection and/or 6 days post CVB3, and CD11chi DCs were puriﬁed by magnetic enrichment (splenocytes were pooled within mouse groups). Naı¨ve CD8þ transgenic
T cells were also puriﬁed by magnetic enrichment from uninfected P14 mice, and then labeled with CFSE. An equal number (6104/well) of puriﬁed DCs from each group
were incubated with puriﬁed P14 T cells (1.2105/well) in vitro. An additional set of cultures included P14 cells incubated with GP33–41 peptide-pulsed puriﬁed DCs from
co-infected mice. Culture wells were harvested on days 2, 3, or 4, and analyzed by ﬂow cytometry. (A) Proliferation (loss of CFSE ﬂuorescence) of P14 T cells. Histograms are
gated on CD8þThy1.1þ cells, and, for each histogram, the percentage of P14 cells that have divided is shown; the gate used to deﬁne P14 division is shown by dotted lines
in the upper left panel. (B) Kinetics of P14 T cell division in vitro. Data show the percentage of total P14 cells in each well that have divided at least once, and are expressed
as the mean7SEM of triplicate wells. (C) Prior to the start of in vitro culture, the puriﬁed DC stimulator populations were analyzed by ﬂow cytometry to determine the
frequency of cDCs subsets. Representative contour plots are gated on CD11chi lineageneg cells. The numbers indicate the proportion of the cDC subset (CD8aþ , CD4þ ,
double negative) in each quadrant, as a percentage of all CD11chi lineageneg cells.
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Second, we examined whether splenic APCs from co-infected
mice present LCMV antigen in a manner that can drive the
proliferation of naı¨ve LCMV-speciﬁc CD8þ transgenic T cells.
We previously demonstrated that mice infected with rCVB3
expressing LCMV immunodominant epitopes mount very weak
endogenous T cell responses in vivo, but the capacity of spleno-
cytes from CVB3-infected animals to stimulate naı¨ve T cells
in vitro was not examined (Kemball et al., 2008; Slifka et al.,
2001). Mice were infected with wtCVB3 and, 4 days later (the
time point when DCs are strongly affected, Fig. 2), the mice
received LCMV. Three groups of control mice received CVB3 alone,
LCMV alone, or no virus. Splenocytes were harvested from the
infected mice at 2 days after LCMV infection and/or 6 days post-
CVB3, and were incubated for 2–4 days in vitro with CFSE-labeled
naı¨ve P14 CD8þ transgenic T cells. Since APCs from the donor P14
spleen could potentially present viral antigens and drive CD8þ
transgenic T cell proliferation independently of APCs from virus-
infected spleens, P14 CD8þ T cells were puriﬁed by magnetic
selection (see Materials and Methods), and these enriched CD8þ T
cells (93% CD8þThy1.1þ) were incubated with splenocytes from
virus-infected mice. CD11chi DCs were almost completely absent
from this enriched CD8þ T cell fraction (0.03% of selected cells
were CD11chiThy1.1CD19CD49b , data not shown), and there-
fore a vanishingly small number of DCs in these cultures origi-
nated from the P14 donor mouse. P14 CD8þ T cell proliferation
was analyzed by ﬂow cytometry after 2, 3, or 4 days of in vitro
culture. The vast majority of P14 cells did not divide (remained
CFSEhi) following stimulation with splenocytes from uninfected
mice, or frommice infected with wtCVB3 only (Fig. 11(A) and (B)).
A substantial proportion (60%) of P14 cells divided (and diluted
their CFSE) after 2 days of stimulation with splenocytes from mice
infected with LCMV only; by day 3 almost all of the input P14
cells had divided, the majority several times, and they continued
to proliferate through day 4 (Fig. 11(A) and (B)). In contrast,
relatively few P14 cells (20%) had begun to proliferate on day
2 after stimulation with splenocytes from co-infected mice. In
addition, prior infection with wtCVB3 altered the CFSE ﬂuores-
cence proﬁles observed after 2 days of in vitro culture (Fig. 11(A)
top row; compare LCMV and co-infected panels): although, in
both cases, the maximum number of observed divisions was 4,
many more cells had undergone 1–4 divisions in response to
splenocytes from mice infected with LCMV alone, compared to
splenocytes from co-infected mice. Thus, wtCVB3 co-infection
appears to diminish the division of naı¨ve LCMV-speciﬁc CD8þ T
cells in vitro, paralleling what we have observed in vivo. However,
as we have also observed in vivo (Fig. 8), the magnitude of the
effect diminishes with time; after 3 days of stimulation by
splenocytes from co-infected mice, the majority of naı¨ve P14 cells
in co-infected culture wells had proliferated, and almost all of the
sensor cells had divided by day 4 (Fig. 11(A) and (B)). To
determine if P14 T cell proliferation increased when the level of
viral antigen presentation by co-infected splenocytes was artiﬁ-
cially increased, we setup an additional group of cultures in which
P14 cells were incubated with co-infected splenocytes together
with GP33–41 peptide. In these wells, a greater percentage of P14
cells (70%) had divided after 2 days of culture, and this was
similar to the proportion of P14 cells that divided following
stimulation with splenocytes from mice infected with LCMV
alone (Fig. 11(A) and (B)). P14 cells stimulated with co-infected
splenocytesþpeptide continued to divide further by day 4 of
culture. Thus, we conclude that the weaker proliferation of P14
cells in co-infected (no peptide) cultures on day 2 most likely
resulted from a lower level of LCMV antigen presentation and/or
fewer APCs presenting viral antigens to T cells; and that this
deﬁciency could be overcome by provision of abundant peptideantigen. In support of this hypothesis, ﬂow cytometric analysis of
the stimulator splenocytes from the various groups showed that,
when added to the wells at the beginning of the culture, the
frequency of CD8aþCD11chi DCs was substantially lower in co-
infected mice compared to mice infected with LCMV alone
(Fig. 11(C)). In summary, these data show that, in co-infected
mice, endogenous LCMV antigen is presented sufﬁciently well to
trigger naı¨ve CD8þ T cell proliferation in vitro. However, T cell
division is delayed compared to that observed with LCMV-only
stimulator cells; this delay appears to result, in part, from a lower
level of viral antigen presentation and/or fewer APCs; and it can
be overcome by the addition of exogenous GP33–41 peptide to co-
infected cultures.
Puriﬁed dendritic cells from LCMV-infected or co-infected mice are
similarly capable of stimulating T cell proliferation in vitro
The data presented in Fig. 11 show that splenic APCs from
co-infected mice can stimulate naı¨ve CD8þ T cell proliferation
in vitro, although the functionality of DCs was not assessed
independently of other splenic APCs. It is unclear whether the
delay in T cell expansion in vitro is due to decreased functionality
of DCs or due to a reduction in their numbers alone. In order to
isolate DC function from that of other APCs, groups of mice were
infected with wtCVB3 and/or LCMV as in Fig. 11, spleens were
harvested (and pooled within mouse groups), and CD11cþ DCs
were puriﬁed by magnetic selection. Flow cytometric analysis
of these puriﬁed DC populations showed a lower frequency of
CD8aþCD11chi DCs in co-infected mice compared to mice
infected with LCMV alone (Fig. 12(C)), in agreement with the
analysis of non-puriﬁed DCs (Fig. 11(C)). An equal number of
puriﬁed DCs from each group were incubated with puriﬁed,
CFSE-labeled, P14 T cells for 2–4 days in vitro. The majority of
P14 cells did not divide (remained CFSEhi) following stimulation
with DCs from uninfected mice, or from mice infected with
wtCVB3 only (Fig. 12(A) and (B)). A substantial proportion
(30%) of P14 cells divided after 2 days of stimulation with DCs
from mice infected with LCMV only; by day 3 most of the input
P14 cells had divided, the majority several times, and they
continued to proliferate through day 4 (Fig. 12(A) and (B)). A
similar response by P14 cells was observed using DCs from co-
infected mice, and the kinetics of P14 cell division were compar-
able in wells containing DCs from co-infected mice or mice
infected with LCMV alone (Fig. 12(A) and (B)). To determine if
P14 T cell proliferation increased when the level of viral antigen
presentation by co-infected DCs was artiﬁcially increased, we
setup an additional group of cultures in which P14 cells were
incubated with GP33–41 peptide-pulsed, puriﬁed DCs from co-
infected mice. In these wells, the vast majority of P14 cells
(95%) had divided after 2 days of culture, and continued to
divide further on day 3 and 4 (Fig. 12(A) and (B)). Taken together,
these data show that when equal numbers of puriﬁed DCs (from
LCMV-only and co-infected mice) are used as stimulators, both
populations are similarly capable of stimulating in vitro T cell
proliferation. Therefore, the delay in T cell division following
stimulation with co-infected splenocytes (Fig. 11(A) and (B)) is
most likely due to the reduced number of DCs present in the
culture wells (compared to splenocytes from mice infected with
LCMV alone), rather than a decrease in DC functionality.Discussion
In vitro studies have suggested that enteroviruses utilize strate-
gies that impair the ability of DCs to trigger adaptive immunity,
by inhibiting protein synthesis within DCs, and by limiting cellular
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secretion. However, it is not known whether picornaviruses exert
similar effects on DCs in vivo, or if other effects of virus infection also
modulate the stimulatory capacity of DCs. Although DC infection by
coxsackievirus has been reported, the extent to which it occurs
in vivo, and the level of protein expression in infected DCs, was
unknown. In the present study, we evaluated the effects of wtCVB3
on DCs in vivo and in vitro, and we make several novel observations:
ﬁrst, viral protein synthesis is extremely limited in DCs and the
relative frequency of infected DCs is very low, both in vitro and
in vivo. Second, wtCVB3 nevertheless substantially affects DCs and
reduces their numbers more profoundly than in other well-char-
acterized viral systems. Third, the severe reduction in CD8aþ cDCs
is associated with a reduced ability of the host to mount T cell
responses to a subsequent viral infection. Finally, DCs obtained from
wtCVB3-infected mice do present antigen in a manner that can
trigger naı¨ve CD8þ T cell responses, but the T cell responses are
delayed, both in vivo and in vitro.
CVB3 does not establish a productive infection in murine DCs
(Weinzierl et al., 2008b), and cannot replicate in human DCs upon
entry via phagocytosis (Schulte et al., 2010). However, a recent
study found that murine DCs can endocytose CVB3 virions, and
reported that DCs isolated from infected mice contain positive
and negative strand viral RNA (Weinzierl et al., 2008b). Thus, we
considered the possibility that DCs may be non-productively
infected by CVB3 in vivo; if viral proteins were generated in
sufﬁcient abundance within infected DCs, they might lead to cell
death and/or inhibit the presentation of MHC class I-restricted
CVB3 epitopes, thereby contributing to the weak primary CVB3-
speciﬁc T cell response, and to the reduction in LCMV-speciﬁc
T cell responses reported herein. However, very few virus-
infected DCs expressing DsRed protein were detected in the
spleen and pancreatic lymph nodes of DsRed-CVB3-infected mice
(Fig. 5). In addition, in vitro exposure of murine DCs to CVB3 at
high multiplicity did not lead to viral protein expression (VP1 or
GFP) at a level detectable by ﬂow cytometry (Fig. 6(A)), and the
cells did not exhibit signiﬁcant changes in their surface expres-
sion of MHC class I and II and CD86 (Fig. 6B and data not shown).
Furthermore, CVB3 did not cause detectable cytopathic effects
and, as others have reported, productive infection did not take
place. We cannot exclude the possibility that a small subset of
DCs is infected by CVB3 in vivo and that, in these cells, direct
presentation of MHC class I-restricted antigens is compromised
by the virus; but these data suggest that CVB3 may elude naı¨ve
CD8þ T cells in large part by the simple expedient of avoiding
DCs, rather than by inhibiting antigen presentation within these
key APCs. However, this raises another issue: even if the virus
does not infect DCs, one would expect that CVB-encoded epitopes
would be presented to naı¨ve CD8þ T cells by DCs that are
specialized for cross presentation/ cross-priming (CD8þCD205þ
DCs). Our previous study suggested that this alternate mode of
entry to the MHC class I pathway does not operate efﬁciently
during CVB3 infection, but the molecular basis for the apparent
failure of cross-priming in CVB3-infected mice has not been
determined (Kemball et al., 2009). One possible explanation is
that these DCs are indirectly affected by CVB3 infection. By this
hypothesis, CVB3 not only evades DCs by failing to infect them, it
also disrupts – probably by indirect means – the DCs that might
otherwise present viral epitopes for cross-priming.
We found that, despite its inability to infect DCs in a wide-
spread fashion, wtCVB3 causes a rapid and profound reduction in
DC numbers (Fig. 1), and alters the relative proportions of the
various cDC subsets (Fig. 2). From the data in Figs. 5 and 6, these
changes are unlikely to be caused by direct infection of DCs;
rather, the CVB3-related reduction in DC numbers is more likely
to be mediated indirectly. Although changes in DC abundance andheterogeneity have been observed in other viral infection models,
our ﬁndings suggest that the reduction in cDCs in CVB3-infected
mice is more profound compared to other virus infections. For
example, the decline in numbers of splenic CD8aþ and CD4þ
cDCs is more modest following LCMV Armstrong infection (2–3
fold reduction by day 3 p.i.), and cDC numbers remain stable (or
increase slightly) following murine cytomegalovirus and g-her-
pesvirus 68 infections (Dalod et al., 2003; Montoya et al., 2005;
Weslow-Schmidt et al., 2007). The reduction in cDCs that follows
LCMV infection is mediated in part by type I IFN signaling
(Montoya et al., 2005). Type I IFN levels peak in the serum of
CVB3- and LCMV-infected mice at a similar time point (24–48 h
p.i.) (Huhn et al., 2010; Lee et al., 2009; Wang et al., 2010; Zuniga
et al., 2008), so we speculate that the reduction of cDCs in CVB3-
infected mice may be mediated by type I IFNs; experiments to
evaluate this hypothesis are particularly challenging in the CVB
model because, in the absence of type I IFN signaling, CVB
infection is invariably lethal within 2–4 days (Wessely et al.,
2001; Kemball et al., unpublished data).
pDC accumulation has been observed in lymphoid and non-
lymphoid tissues during virus infections in mice and humans, and
the recruitment of pDCs can either positively or negatively affect
the antiviral immune response (Swiecki and Colonna, 2010a).
Following CVB3 infection, we found that the total number and
frequency of pDCs increases dramatically between day 4 and day
6 days p.i. (Fig. 1(D) and (F)). In addition, ﬂow cytometric analysis
of splenic pDCs in virus-infected mice (from day 4 onward)
showed that these cells are considerably larger in size compared
to pDCs in uninfected animals, and suggests that these cells have
been activated, and are blasting and/or mature (data not shown).
The dramatic increase in pDC numbers cannot be attributed to
activated T cells that up-regulated the DC marker CD11c, because
our pDC gating strategy excluded cells that expressed the T cell
marker CD3 (Fig. 1(F)). During CVB3 infection, pDC activation
appears to require engulfment of virus-antibody complexes, and
results in TLR-7-dependent production of type I IFN (Wang et al.,
2007). Thus, the antiviral effects of pDCs in response to wtCVB3
may be delayed until antiviral antibodies have developed, and we
speculate that the dramatic increase in pDC numbers at day 6 is
temporally associated with the emergence of virus-speciﬁc anti-
bodies that facilitate pDC activation. CVB3 antibodies are detect-
able by day 4 p.i. (Henke et al., 1995) which, as shown in
Fig. 1(D), coincides with an increase in the number of pDCs in the
spleen of infected mice. Unlike mature cDCs, activated pDCs do
not down-regulate MHC class II ubiquitination and turnover, and
as a result new MHC class II-peptide complexes are continually
generated following pDC maturation (Villadangos and Young, 2008;
Young et al., 2008). Therefore, we propose that, at day 4 and
beyond, when cDCs are fewer in number, pDCs may play a role in
CVB3 immunity by maintaining MHC class II presentation of CVB3
epitopes to CVB3-speciﬁc CD4þ T cells.
The loss of cDCs that occurs at 3–4 days after wtCVB3 infection
is striking, and prompted us to question whether wtCVB3 infec-
tion diminishes the ability of an infected animal to mount T cell
responses to a secondary infection. We have previously demon-
strated that rCVB3 infection has no such effect (Kemball et al.,
2009), but rCVB3 are generally attenuated in vivo, and we
considered it vital to evaluate the effects of the wt virus. In stark
contrast to rCVB3, we found that wtCVB3 infection dampened
CD8þ and CD4þ T cell responses to subsequent LCMV infection;
the magnitude of LCMV-speciﬁc T cell responses at day 7 post
LCMV were considerably reduced (Z10-fold) in mice that had
received wtCVB3 4 days prior to LCMV (Fig. 7(D) and (E)). This
suppressive effect of wtCVB3 infection was rapid, and could be
observed even when LCMV was administered only 2 days after
CVB3; the total number of LCMV-speciﬁc T cells was strongly
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because, by day 7 post LCMV, there was only a modest difference
in the magnitude of the T responses in co-infected mice compared
to those in mice infected with LCMV alone (Fig. 8(D)–(F)). Thus,
wtCVB3 infection delays LCMV-speciﬁc T cell expansion, but does
not prevent it. Furthermore, dysfunctional cells were not identi-
ﬁed in co-infected mice (Fig. 8(D), (E), (G) and (H)), indicating
that, although slower to accumulate, the responding effector T
cells in these mice are functionally competent and produce
antiviral cytokines. Thus, wtCVB3 infection dampens, but does
not ablate, host CD8þ T cell immunity.
The most obvious explanation for the lower LCMV-speciﬁc T
cell responses in co-infected mice invokes the wtCVB3-related
changes in DC quantity and quality. Our analysis of cDC numbers
in co-infected mice, and mice infected with wtCVB3 alone,
showed that these cells were signiﬁcantly diminished and to
a similar extent in both groups (Figs. 1, 2 and 9). It is easy to
imagine how the substantial reduction in DC numbers caused by
wtCVB3 at 3 and 4 days p.i. (Figs. 1 and 2) might diminish the
host’s ability to mount primary T cell responses to subsequent
LCMV infection, and our in vitro stimulation data (Fig. 11) are
consistent with this hypothesis. Compared with splenocytes from
mice infected with LCMV alone, the frequency of CD8aþ DCs was
substantially lower in co-infected stimulator splenocytes (day
2 post LCMV/day 6 post CVB3, Fig. 11C), and these ‘‘CD8aþ DC-
depleted’’ splenocytes induced fewer LCMV-speciﬁc T cells to
proliferate after 2 days of in vitro culture (Fig. 11A and B). In
contrast, when equal numbers of puriﬁed DCs (from LCMV-only
and co-infected mice) were used as stimulators, both popula-
tions were similarly capable of stimulating T cell proliferation
(Fig. 12(A) and (B)). Together, these data suggest that the delayed
T cell responses to co-infected splenocytes in vitro are due to a
reduction in DC numbers rather than a decrease in DC function-
ality. The impact of these quantitative differences may be ampli-
ﬁed by the qualitative changes in the APCs that are rapidly
induced by wtCVB3 infection in vivo. Qualitative changes (e.g.,
cell maturation) in CD8aþ DCs occur as early as day 2 p.i. (Fig. 4),
preceding their numerical collapse (Fig. 2(D) and (E)), and we
speculate that these changes may contribute both to the delayed
T cell response when LCMV is administered at this time point
(Fig. 8) and to the delayed T cell response that is observed in vitro
(Fig. 11). However, qualitative changes alone may not have
irredeemable effects because, in mice infected with LCMV at
2 days after wtCVB3 infection, the magnitude of the LCMV-
speciﬁc CD8þ T cell response in these mice is only modestly
reduced 7 days later (Fig. 8); similarly, P14 T cell proliferation
in vitro appears to progress normally by day 3–4 (Fig. 11). Based
on these ﬁndings we speculate that, in mice that receive LCMV
shortly after CVB3 (2 days later, Fig. 8), the kinetics of LCMV-
speciﬁc T cell expansion are altered because wtCVB3 infection
reduces DC quality, delaying (but not aborting) the expansion of
LCMV-speciﬁc T cells. If the interval between these infections is
increased (e.g., if LCMV is given 3 or 4 days after CVB3), both
quality and quantity are markedly reduced, thereby amplifying
the suppressive effect of wtCVB3 on the LCMV T cell response. In
contrast, if LCMV is given 3 days after rCVB3 infection, LCMV-
speciﬁc T cell responses are enhanced, which suggests that the
less virulent recombinant virus does not exert these suppressive
effects on DCs; rather, rCVB3 infection appears to establish a
microenvironment that is capable of promoting strong T cell
responses against a subsequent virus infection (Kemball et al.,
2009). We considered the possibility that the weaker LCMV-
speciﬁc T cell response in CVB3-infected mice might result
from a reduced level of LCMV antigen, perhaps because LCMV
replication was suppressed by ongoing host responses to the
CVB3 infection. However, our quantitative assessment of LCMVgenomes in the spleen and liver suggests that LCMV replication is
not limited by CVB3 co-infection. On the contrary, the number of
LCMV genomes in these organs was similar to, or slightly greater
than, the number measured in mice infected with LCMV alone
(Fig. 10). Indeed, our ﬁnding that LCMV genome copy numbers were
signiﬁcantly higher in the livers of co-infected mice, which lack
strong LCMV-speciﬁc T cell responses, is consistent with the fact
that control of LCMV is T cell-dependent (Ahmed et al., 1988, 1984;
Jamieson et al., 1987). It is unclear why LCMV replication is not
inhibited by the innate immune response to CVB3. Levels of type I
IFN peak in the serum and pancreas of CVB3-infected mice at day
2 p.i. (the time point at which mice were co-infected with LCMV,
Fig. 8), but this increase is not observed in the liver (Huhn et al.,
2010; Wang et al., 2010). Therefore, it is conceivable that LCMVmay
escape the effects of CVB3-induced type I IFN in some sites including
the liver and spleen. Furthermore, CVB3 can disrupt type I IFN
signaling in vitro by cleaving the innate immune adapter molecules
MAVS and TRIF, and we speculate that antagonism of these signaling
pathways by CVB3 in vivo could minimize the effects of type I IFN on
concurrent LCMV replication (Mukherjee et al., 2011).
The effects of CVB3 on DCs, and in particular CD8þCD205þ
DCs, may contribute to our previous ﬁndings that CD8þ T cell
responses to CVB3 are barely detectable (Kemball et al., 2009,
2008; Slifka et al., 2001). However, we feel that additional factors
must play a role, for several reasons. First, activation of DCs is
known to decrease their ability to cross-prime naı¨ve virus-speciﬁc
T cells (Segura and Villadangos, 2009; Wilson et al., 2006; Young
et al., 2007); consequently, cross-priming is thought to occur very
soon after the onset of infection, when naı¨ve CD8þ T cells interact
brieﬂy with immature antigen-bearing DCs (Hickman et al., 2008;
Kastenmuller et al., 2010; Norbury et al., 2002). One would expect
that CVB3 proteins synthesized in the ﬁrst hours p.i. would gain
access to, and be cross-presented by, immature DCs, prior to
their being activated by the infection. This appears not to occur.
Second, we show here that a wtCVB3-infected host remains
capable of mounting a strong (albeit slightly delayed) response
as late as 2 days after wtCVB3 infection (Fig. 8). At this time point,
CD8aþ DCs are numerous, and wtCVB3 has replicated to high
titers (Fig. 1A), so viral proteins are abundant, yet mice do not
develop a readily-detectable CVB3-speciﬁc CD8þ T cell response
(Kemball et al., 2009); this suggests that the existing CD8aþ DCs
do not effectively cross-prime in these wtCVB-infected mice.
Third, even when DCs are largely depleted by wtCVB3 infection
(day 4 p.i.) the host remains capable of mounting a detectable
response to LCMV. We cannot exclude other, DC-independent,
explanations that may contribute to the weak primary T cell
response to CVB, and for the diminished LCMV-speciﬁc T cell
response in wtCVB3-infected mice. For example, somewhat
counter-intuitively, many viruses cause a rapid but transient
lymphopenia (Bautista et al., 2003; Dı´az-San Segundo et al.,
2006; Dietz, Jr. et al., 1979; Geisbert et al., 2000; Grubman
et al., 2008; Nfon et al., 2010; O’Donnell and Carrington, 2002;
Okada et al., 2000; Peacock et al., 2003); the effect, which is
mediated by interferons (Kamphuis et al., 2006; Schattner et al.,
1983), has been shown to occur during enteroviral infections
(Bautista et al., 2003; Nfon et al., 2010) and we have observed it in
mice infected with wtCVB3 (Althof and Whitton, unpublished data).
In conclusion, our evaluation of the effects of wtCVB3 on DCs
in vitro and in vivo reveals that the infection dramatically alters
the abundance, heterogeneity, and immunostimulatory capacity
of conventional dendritic cells. These changes are unlikely to be
the result of direct infection of DCs by CVB3, and instead the
virus appears to induce DC maturation and decay in an indirect
manner. The loss of CD8aþ DCs may deprive the host of the
most potent inducers of virus-speciﬁc T cell responses, and other
effects on cDCs, e.g., on activation/maturation, may augment the
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These features also may weaken the host’s capacity to mount T
cell responses to a secondary virus infection.Materials and methods
Mice, viruses, and infections
C57BL/6J mice were purchased from The Scripps Research
Institute (TSRI) breeding facility. P14/Thy1.1 TCR transgenic mice
speciﬁc for the H-2Db restricted LCMV epitope GP33–41 (Pircher
et al., 1990) were bred and maintained by our laboratory as
described (Whitmire et al., 2006; Whitmire et al., 2008). This
study was carried out in accordance with the recommendations in
the Guide for the Care and Use of Laboratory Animals of the
National Institutes of Health. All experimental procedures with
mice were reviewed and approved by TSRI Animal Care and Use
Committee. The wtCVB3 used in these studies is a plaque-puriﬁed
isolate (designated H3) of the myocarditic Woodruff variant of
CVB3 (van Houten et al., 1991). Plasmid pH3, encoding a full
length infectious clone of this virus (Knowlton et al., 1996), was
provided by Kirk Knowlton (University of California, San Diego,
CA). Recombinant CVB3 encoding eGFP or DsRed were generated
as described previously (Feuer et al., 2002; Tabor-Godwin et al.,
2010). wtCVB3, eGFP-CVB3, and DsRed-CVB3 were grown in HeLa
cells, and virus stocks were generated as described previously
(Harkins et al., 2005). Naı¨ve adult male C57BL/6J mice were
inoculated i.p. with 1103 pfu of wtCVB3, 1107 pfu of DsRed-
CVB3, or 2105 pfu of LCMV Armstrong. To conﬁrm CVB3
infection, the virus titer in the feces was determined on day
2 post infection, as described previously (Kemball et al., 2009).
Pancreas was isolated from wtCVB3-infected mice, weighed, and
homogenized in 1 ml DMEM, and the titer of infectious virus in
the lysate was determined. Plaque assays were performed on
subconﬂuent HeLa cell monolayers, as described previously
(Hunziker et al., 2007), and the virus titer (pfu/g) was calculated
for each sample.
Lymphocyte isolation
Spleens and pancreatic lymph nodes were minced and
digested with collagenase D (1 mg/ml, Roche) and DNase I
(20 mg/ml, Roche) for 30 min at 37 1C, and then ﬁltered through
a 70 mm cell strainer (BD Biosciences) to generate a single cell
suspension. Red blood cells were lysed with 0.83% NH4Cl.
Isolation and culture of bone marrow-derived dendritic cells
Bone marrowwas ﬂushed from the femurs and tibiae of C57BL/6J
mice using cold DPBS (Invitrogen). Marrow was passed repeatedly
through an 18-gauge needle and then ﬁltered through a 70 mm cell
strainer to generate a single cell suspension. Viable cells were
separated from dead cells and erythrocytes using Lympholyte-M
(Cedarlane Labs), according to the manufacturer’s instructions. Cells
were setup in 24-well plates (12106 cells/well) in 1 ml of BMDC
culture media (RPMI containing 10% FBS, L-glutamine, 2-mercap-
toethanol, penicillin/streptomycin, sodium pyruvate, and HEPES)
with recombinant murine GM-CSF (50 ng/ml, Peprotech), and cul-
tured for 6–10 days before use. On day 2, 700 ml of media was
removed from each well and replaced with fresh mediaþGM-CSF.
On day 3, the entire volume of media was removed from the wells,
then the cells were gently washed with 500 ml fresh media (to
remove residual non-adherent cells), and 1 ml of culture med-
iaþGM-CSF was added to the wells. Thereafter, cells were fed daily
with 1 ml culture mediaþGM-CSF.In vitro antigen presentation assay
Transgenic T cells were used to detect the presentation of
LCMV antigen by splenocytes isolated from virus-infected mice.
To prepare these indicator cells, CD8þ T cells were puriﬁed from
the spleens of P14/Thy1.1 TCR transgenic mice by MACS separa-
tion (negative selection) using a mouse CD8aþ T cell Isolation Kit
II (Miltenyi Biotec), following the manufacturer’s instructions. The
purity of enriched CD8þ T cells (93%) and the frequency of P14
transgenic T cells (CD8þVa2þ) were determined by ﬂow cyto-
metry. P14 cells were labeled with 3 mM CFSE. Single cell
suspensions of spleens from virus-infected mice were prepared
(see Lymphocyte isolation, above), and 106 stimulator spleen cells
were incubated with 5104 P14 transgenic T cells per well in 96-
well ﬂat bottom plates containing 0.2 ml culture media (RPMI
containing 10% FBS, 50 mM 2-mercaptoethanol, and penicillin/
streptomycin). One set of cultures included P14 cells, splenocytes
from co-infected mice, and 1 mM LCMV GP33–41 peptide. Duplicate
cultures were setup for each sample. Cells were fed on day 2 and
3 of culture; 1/2 the volume of media from each well was
removed, and replaced with 100 ml fresh culture media. Wells
were harvested after 2, 3, and 4 days of culture, and transgenic T
cell proliferation was determined by ﬂow cytometry.
To analyze antigen presentation by DCs, these cells were
enriched from the spleens of virus-infected mice by MACS
separation (positive selection) using mouse CD11c microbeads
(Miltenyi Biotec), following the manufacturer’s instructions. The
spleens within each mouse group (3–6 mice/group) were pooled
before MACS separation. 6104 CD11chi cells were incubated
with 1.2105 CFSE-labeled P14 cells per well. In one set of cultures,
DCs from co-infected mice were pulsed with 1 mM GP33–41
peptide for 30 min in 96-well culture wells (1.2105 cells/well),
then washed to remove unbound peptide, and incubated with P14
cells. Triplicate cultures were setup for each group. Wells were
harvested after 2, 3, and 4 days of culture, and transgenic T cell
proliferation was determined by ﬂow cytometry.
Flow cytometry
Cells were incubated with Fc receptor antibody (FcBlock, BD
Biosciences) in PBS containing 2% FBS and 0.1% sodium azide
(FACS buffer) for 10 min on ice. Cells were then surface stained
with ﬂuorochrome-conjugated antibodies and/or MHC class I
tetramers (NIH Tetramer Core Facility, Atlanta, GA) in FACS buffer
for 30 min on ice, and washed 2X in FACS buffer. Following the
surface staining, some samples were stained with eFluor780-
conjugated ﬁxable viability dye (eBioscience) following the man-
ufacturer’s instructions, in order to identify dead cells during ﬂow
cytometry and exclude them from our analyses. Samples were
ﬁxed in PBS containing 1% paraformaldehyde and acquired on a
FACSCalibur or LSR-II (BD Biosciences). Data were analyzed with
FlowJo software (TreeStar).
For intracellular cytokine staining of splenocytes, 2106 sple-
nocytes were incubated for 5 h in 96-well plates in 0.2 ml/well
RPMI containing 10% FBS, 50 mM 2-mercaptoethanol, penicillin/
streptomycin, GolgiPlug (BD Biosciences), and synthetic peptides
(1 mM LCMV GP33–41 or NP396–404, 10 mM GP61–80). After stimula-
tion, cells were incubated with FcBlock, stained with CD8 or CD4
antibodies as described above, then stained for intracellular IFNg
with the Cytoﬁx/Cytoperm kit (BD Biosciences). The total number
of epitope-speciﬁc cytokine-producing T cells was determined by
subtracting unstimulated cytokineþ T cells (no peptide) from
peptide-stimulated cytokineþ T cells.
For intracellular staining of CVB3-infected primary BMDCs and
cell lines [including DC2.4 cells (kindly provided by Ken Rock,
University of Massachusetts) and HeLa cells], cells were detached
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versene (Invitrogen), and then washed and resuspended in FACS
buffer. Cells were permeabilized with the Cytoﬁx/Cytoperm kit,
and then stained with VP1 antibody in Permwash for 30 min
on ice.
The following antibodies were used for the ﬂow cytometric
analyses described above. Fluorochrome-conjugated CD11c (clone
N418), CD11b (clone M1/70), CD3e (clone 145-2C11), CD19 (clone
6D5), CD49b (clone DX5), CD8a (clone 53-6.7), CD4 (clone RM4-5
and GK1.5), Thy1.1 (clone HIS51), Thy1.2 (clone 53-2.1), Va2
(clone B20.1), MHC class I (clone 28-14-8), MHC class II (clone
M5/114.15.2), CD40 (clone HM40-3), CD80 (clone 16-10A1), CD86
(clone GL1), IFNg (clone XMG1.2), and isotype control antibodies
were purchased from eBioscience or BioLegend. CD205 (clone
NLDC-145) and mPDCA-1 (clone JF05-1C2.4.1) antibodies were
purchased from Miltenyi Biotec. VP1 antibody (clone 5-D8/1) was
purchased from Leica Microsystems as a lyophilized tissue culture
supernatant. The antibody was reconstituted in water, column
puriﬁed by TSRI Antibody Core Facility, and conjugated to Alexa
Fluor 647 using a Molecular Probes monoclonal antibody labeling
kit (Invitrogen).
Vibratome sectioning and confocal microscopy
Mice were perfused with DPBS, and the pancreas was har-
vested and ﬁxed in buffered zinc formalin (Z-FIX, Anatech Ltd.) at
RT for 5 days. The ﬁxative was replaced with PBS and tissues were
preserved at 4oC. Sections of pancreas (80 mm) were cut with a
VT1000 S vibratome (Leica Microsystems, Inc.). Free ﬂoating
sections were washed 3 times in PBS and permeabilized in PBS
with 0.5% Triton X-100 for 30 min at RT. Next, the sections were
washed twice in PBS with 0.1% Triton X-100 and then incubated
with Alexa Fluor 488-conjugated phalloidin (Invitrogen) in PBS
with 0.1% Triton X-100 overnight at 4 oC (to label F-actin). After
incubation, the sections were washed twice in PBS with 0.1%
Triton X-100 and then 3 times in PBS. Lastly, sections were
stained with Hoechst 33342 (Invitrogen) in PBS for 30 min at RT
(to label nuclei) and then washed 3 times in PBS and mounted on
glass slides with ProLong Gold mounting medium (Invitrogen).
Three color images were captured using a LSM 710 laser scanning
confocal microscope equipped with ZEN software (Carl Zeiss,
Inc.). Representative regions within each vibratome section of
pancreas were scanned at 40 magniﬁcation as serial 8-bit
optical sections with 0.5 mm interval step sizes (512 by 512 image
size). Images were analyzed with Imaris software (BitPlane, Inc.)
and maximum projected for presentation using the Easy 3D
function.
Quantitative real time PCR
Spleen and liver samples were collected and immediately stored
in RNAlater stabilization reagent (Qiagen). RNA was isolated from
these organs with an RNeasy mini kit (Qiagen), following the
manufacturer’s instructions, and genomic LCMV RNA (present in
mature virions) was quantitated as follows. A reverse transcription
(RT) primer (50CAGGGTGCAAGTGGTGTGGTAAGA30) complementary
to residues 2865 to 2842 of the viral S segment genomic RNA was
synthesized, and used in an RT reaction together with 1/10th of the
total RNA sample, MultiScribe RT, 10 PCR Buffer II, MgCl2, RNAse
Inhibitor, and GeneAmp dNTP Mix (all from Applied Biosystems).
Additional control reactions were setup that omitted RT (‘‘no RT’’).
The RT reaction was carried out in a thermocycler as follows:
25 1C for 10 min, 48 1C for 30 min, 95 1C for 5 min. Next, Taqman
quantitative real time PCR was performed using the following
primers and probe: forward primer (Arm S 2275þ), 50CGCTGGC-
CTGGGTGAAT30; reverse primer (Arm S 2338-), 50ATGGGAAAACA-CAACAATTGATCTC30, Taqman FAM/MGB-labeled probe, 50TTGCTG-
CAGAGCTTA30. PCR reactions contained primers and probe, TaqMan
Universal PCR Master Mix (No AmpErase UNG, Applied Biosystems),
and 1/10th of the total cDNA. Quantitative analysis of viral RNA was
carried out using a BioRad iQ5 real time PCR system in 96-well
optical reaction plates heated to 95 1C for 10 min, followed by
40 cycles of: denaturation at 95 1C for 15 s and annealing and
extension at 60 1C for 1 min. All samples were evaluated in triplicate
ampliﬁcation reactions. Dilutions of the p-T7-S plasmid (encoding
the S segment of the LCMV Armstrong genome, kindly provided by
Juan Carlos de la Torre, TSRI) were analyzed (in quadruplicate) to
generate a standard curve. The standard curve was based on
threshold cycle (CT) values, and CT values from tissue samples were
compared to the standard curve to determine viral RNA copy
numbers. The limit of detection of this assay is 5 copies of viral
RNA/reaction. Values are expressed as the average number of LCMV
genomes per mg tissue; these were determined by calculating the
total number of LCMV genomes per RNA sample, divided by the
sample weight.
Statistical analyses
Statistical signiﬁcance was determined by an unpaired two-
tailed t-test, or by one-way ANOVA with Tukey’s post hoc test
(GraphPad Prism software). A p value o0.05 was considered
statistically signiﬁcant.Acknowledgments
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